Group 1 - The core point of the announcement is the approval of the 2025 interim profit distribution plan by the company's board, which will be submitted for shareholder approval [1] - The total profit available for distribution to shareholders for the first half of 2025 is approximately 5.24 billion yuan, while the profit available for distribution from the parent company is approximately 590.23 million yuan [1] - The proposed cash dividend is 3.4835 yuan per 10 shares, totaling approximately 400.05 million yuan to be distributed to shareholders [1][2] Group 2 - The cash dividend plan will be adjusted if there are changes in the total share capital due to share buybacks, stock incentive plans, or refinancing [2] - The cash dividend amounts for previous years are as follows: 412.41 million yuan for 2024 and 369.51 million yuan for 2023 [2] - The company has completed share buybacks totaling approximately 153.09 million yuan in the first half of 2025 [2][3] Group 3 - The distribution plan complies with relevant regulations and guidelines, ensuring legality, compliance, and reasonableness [3] - The audit committee has approved the profit distribution plan, stating it aligns with the company's long-term development and does not harm the interests of shareholders, especially minority shareholders [3]

Core Viewpoint - The report highlights the financial performance and strategic initiatives of Apeloa Pharmaceutical Co., Ltd. for the first half of 2025, indicating a decline in revenue and net profit while emphasizing ongoing efforts in innovation and operational efficiency [1][6][8]. Financial Performance - The company reported a revenue of CNY 5,444.49 million, a decrease of 15.31% compared to the previous year [6][8]. - The net profit attributable to shareholders was CNY 520.55 million, down 13.59% year-on-year [6][8]. - Basic earnings per share decreased by 9.14% to CNY 0.4861 [6][8]. Business Overview - The company operates in four main business segments: raw material intermediates, CDMO (Contract Development and Manufacturing Organization), pharmaceuticals, and medical beauty raw materials [7][21]. - The raw material intermediates business includes various series such as cephalosporins and penicillins, while the CDMO segment has seen a 20.32% increase in revenue [9][10]. Industry Context - The biopharmaceutical industry is undergoing significant transformation, driven by technological advancements and an aging population, with the global pharmaceutical market projected to reach USD 2.5 trillion by 2030 [12][13]. - The CDMO market is expected to grow from USD 146.29 billion in 2024 to USD 180 billion in 2025, indicating a robust demand for integrated pharmaceutical services [12][13]. Strategic Initiatives - The company is committed to its "2030 Development Strategy," focusing on enhancing its core competencies in raw materials, strengthening CDMO capabilities, and expanding its pharmaceutical offerings [7][8]. - Ongoing investments in R&D and technology platforms aim to improve production efficiency and product quality, with a focus on automation and digitalization [19][24]. Research and Development - The company employs 1,155 R&D personnel, with significant investments in various technology platforms to support its API and CDMO businesses [23][24]. - Recent achievements include the approval of three API products and one domestic formulation, reflecting the company's commitment to innovation [14][15]. Regulatory Environment - The pharmaceutical industry is experiencing a wave of policy changes aimed at enhancing drug quality and pricing mechanisms, which are expected to support sustainable growth [13][26]. - The company has successfully passed multiple audits from international regulatory bodies, ensuring compliance with high-quality standards [25][26].

Core Viewpoint - The report highlights a decline in revenue and net profit for the first half of 2025 compared to the same period in 2024, indicating potential challenges in the company's financial performance [2][3]. Financial Performance - Operating revenue for the first half of 2025 was approximately 5.44 billion yuan, a decrease of 15.31% from 6.43 billion yuan in the same period last year [2][3]. - Net profit attributable to shareholders was about 563 million yuan, down 9.89% from 625 million yuan in the previous year [2][3]. - The net profit after deducting non-recurring gains and losses was not specified but indicates a decline in overall profitability [2]. - The net cash flow from operating activities was approximately 407 million yuan, reflecting a significant drop of 58.48% from nearly 981 million yuan in the previous year [2][3]. - Basic earnings per share were 0.4861 yuan, a decrease of 9.14% from 0.5350 yuan [3]. Asset and Equity Position - Total assets at the end of the reporting period were approximately 12.48 billion yuan, down 1.93% from 12.73 billion yuan at the end of the previous year [3]. - Net assets attributable to shareholders were about 6.75 billion yuan, showing a slight increase of 0.10% from 6.74 billion yuan [3]. Shareholder Information - The largest shareholder, Hongdian Group, holds 28.57% of the shares, amounting to approximately 330.94 million shares [3]. - Other significant shareholders include Zhejiang Hongdian Import and Export Co., Ltd. with 13.51% and Zhejiang Hongrun Technology Co., Ltd. with 5.15% [3]. Important Matters - There were no significant matters reported during the period [5].

Core Points - The company held the 10th meeting of the 9th Supervisory Board on August 18, 2025, with all three supervisors present [1] - The meeting approved the full and summary report for the first half of 2025, with unanimous support [1] - The board also approved a proposal to adjust the organizational structure and amend the company's articles of association, pending shareholder approval [1] - A mid-year profit distribution plan for 2025 was also approved, which will require shareholder approval [1] Summary by Categories - **Meeting Details** - The meeting was convened on August 18, 2025, with all three supervisors present, ensuring compliance with relevant laws and company regulations [1] - **Financial Reporting** - The Supervisory Board approved the 2025 half-year report in full and summary form, with a unanimous vote of 3 in favor [1] - **Organizational Changes** - A proposal to adjust the organizational structure and amend the company's articles of association was approved, pending further review by the shareholders [1] - **Profit Distribution** - The mid-year profit distribution plan for 2025 was approved unanimously, also pending shareholder approval [1]

Core Points - The company held its 14th meeting of the 9th Board of Directors on August 18, 2025, with all 7 directors present, and approved several key resolutions [1][2][5] - The company approved the full and summary report for the first half of 2025, with unanimous support from the board [1][5] - The board decided to adjust its composition, increasing the number of directors from 7 to 9, adding one non-independent director and one employee representative director [1][2] Governance Structure Adjustments - The Strategic Committee was renamed to the Strategic and ESG Committee, reducing its members from 7 to 5, with the chairman serving as the head [2] - The Audit Committee's membership was reduced from 5 to 3, with two independent directors, one of whom is an accounting professional, serving as the head [2] - The Nomination Committee and the Compensation and Assessment Committee were both reduced to 3 members, with two independent directors in each [2][3] Institutional Revisions - The company approved multiple revisions to its internal regulations, including the Articles of Association, rules for shareholder meetings, and board meeting rules, all requiring shareholder approval [2][3][4] - The company also revised various management systems, including those for fundraising, external investments, and guarantees, with unanimous board support [3][4][5] New Director Nomination - The board nominated Mr. Li Baoping as a candidate for a non-independent director position, pending approval at the upcoming shareholder meeting [4][5] - Mr. Li has extensive experience in management and currently holds several positions within the controlling shareholder's companies [7] Profit Distribution and Shareholder Meeting - The board approved the mid-year profit distribution plan for 2025, which will also be submitted for shareholder approval [5] - A proposal for convening the first temporary shareholder meeting of 2025 was also approved [5]

证券交易所业务规则和《公司章程》等规定。 证券代码：000739 证券简称：普洛药业 公告编号：2025-46 普洛药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况： （1）现场会议召开时间：2025 年 9 月 8 日下午 14:30 （2）网络投票时间：2025 年 9 月 8 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 8 日：9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易所互联网投票系统 进行网络投票的具体时间为 2025 年 9 月 8 日 09:15 至 15:00 的任意时间。 （1）在股权登记日持有公司股份的普通股股东或其代理人； 于股权登记日下午收市时在中国证券登记结算有限责任公司登记在册的公司全体 普通股股东均有权出席股东大会，并可以以书面形式委托代理人出席会议和参加表决， 该股东代理人不必是本公司股东（授权委托书详见附件 1）。 （2）公司董事、监事和高级管理人员； （3）公司聘请的律师； （4）根据相关法规应当出席股东 ...

普洛药业公告，2025年上半年营业收入54.44亿元，同比下降15.31%。净利润5.63亿元，同比下降 9.89%。公司拟向全体股东每10股派发现金红利3.48元（含税）。 ...

普洛药业股份有限公司 董事会议事规则 第一章 总则 第一条 为规范普洛药业股份有限公司（以下简称"公司"）董事会的议事方 式和决策程序，促使公司董事会有效履行职责，提高公司董事会工作效率和科学 决策水平，根据《公司法》、《证券法》、《上市公司治理准则》及《公司章程》等 有关规定，结合公司实际情况，制定本规则。 第二条 公司董事会由九名董事组成（其中独立董事三名，职工代表董事一 名），设董事长一人，副董事长一人。董事会对股东大会负责。 公司董事会下设战略与 ESG（环境、社会和公司治理）委员会、审计委员会、 提名委员会、薪酬与考核委员会四个专门委员会。专门委员会对董事会负责，依 照公司章程和董事会授权履行职责，提案应当提交董事会审议决定。专门委员会 成员全部由董事组成，其中审计委员会、提名委员会、薪酬与考核委员会中独立 董事占多数并担任主任委员（召集人），审计委员会的主任委员（召集人）为会 计专业人士。 第三条 董事会应当坚持民主集中制和实事求是的原则，充分发表意见，反 复讨论，集体决策。董事会成员应当遵守保密原则，在信息未公开披露前不得随 意泄露董事会会议的相关内容。 （十）决定聘任或者解聘公司总经理、董事会 ...

普洛药业股份有限公司 重大信息内部报告制度 （一）公司董事、高级管理人员； （二）公司各事业部、职能部门负责人； 第一章 总 则 第一条 为规范普洛药业股份有限公司（以下简称"公司"）重大信息内部报告工作， 确保公司内部重大信息的快速传递、归集和有效管理，及时、准确、全面、完整地披露 信息，切实维护投资者的合法权益，根据《公司法》、《证券法》、《深圳证券交易所股票 上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号--主板上市公司规范运作》、 《深圳证券交易所上市公司自律监管指引第 5 号—信息披露事务管理》等法律法规及《公 司章程》、《公司信息披露事务管理制度》等有关规定，结合公司实际情况，特制定本制 度。 第二条 本制度所称重大信息是指公司发生或将要发生可能对公司股票及其衍生品 种的交易价格产生较大影响的尚未公开的信息事项。 第三条 重大信息报告是指本制度所规定的重大信息发生或将要发生时，信息报告义 务人应当在知悉当日内及时将有关信息向公司董事长和董事会秘书报告。 第四条 本制度适用于公司及各事业部、职能部门、下属公司（包括公司合并财务报 表范围内的所有下属公司）。 第五条 本制度所述信息报告义务 ...

普洛药业股份有限公司 独立董事工作制度 第一章 总则 第一条 为完善普洛药业股份有限公司（以下简称"公司"）的法人治理结构，规范公 司运作，维护公司整体利益，保障全体股东特别是中小股东的合法权益，充分发挥独立董 事在公司治理中的作用，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上 市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第1号—主板上市公 司规范运作》和《公司章程》等有关规定，结合公司的实际情况，制定本制度。 第二条 独立董事是指不在公司担任除董事以外的其他职务，并与本公司及其主要股 东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独立客观判断关 系的董事。 第三条 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人或者其他 与公司存在利害关系的单位或个人的影响。 独立董事原则上最多在三家境内上市公司担任独立董事，并应当确保有足够的时间和 精力有效地履行独立董事的职责。 第四条 独立董事对公司及全体股东负有忠实和勤勉义务，应当按照相关法律法规和 公司章程的要求认真履行职责，维护公司整体利益，尤其要关注中小股东合法权益不受损 害。 第五条 独立董事占公 ...